We are analyzing https://link.springer.com/article/10.1007/s00262-008-0463-z.

Title:
Development of a Listeria monocytogenes based vaccine against prostate cancer | Cancer Immunology, Immunotherapy
Description:
Prostate specific antigen (PSA) is a likely immunotherapeutic target antigen for prostate cancer, the second leading cause of cancer-related death in American men. Previously, we demonstrated that attenuated strains of Listeria monocytogenes (Lm) can be used as effective vaccine vectors for delivery of tumor antigens causing regression of established tumors accompanied by strong immune responses toward these antigens in murine models of cancer. In the present study, we have developed and characterized a recombinant live attenuated L. monocytogenes/PSA (Lm–LLO–PSA) vaccine with potential use for the treatment of pCa. Human PSA gene was cloned into and expressed by an attenuated Lm strain. This recombinant bacterial vaccine, Lm–LLO–PSA was tested for stability, virulence, immunogenicity and anti-tumor effects in a murine model for pCa. Immunization with Lm–LLO–PSA was shown to lower the number of tumor infiltrating T regulatory cells and cause complete regression of over 80% of tumors formed by an implanted genetically modified mouse prostate adenocarcinoma cell line, which expressed human PSA. Lm–LLO–PSA was immunogenic in C57BL/6 mice and splenocytes from mice immunized with Lm–LLO–PSA showed significantly higher number of IFN-γ secreting cells over that of the naïve animals in response to a PSA H2Db-specific peptide, as measured by both, ELISpot and intracellular cytokine staining. In addition, using a CTL assay we show that the T cells specific for PSA were able to recognize and lyse PSA-peptide pulsed target cells in vitro. In a comparison study with two other PSA-based vaccines (a pDNA and a vaccinia vaccine), Lm–LLO–PSA was shown to be more efficacious in regressing established tumors when used in a homologues prime/boost regimen. Together, these results indicate that Lm–LLO–PSA is a potential candidate for pCa immunotherapy and should be further developed.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

google, scholar, article, pubmed, cancer, cas, prostate, vaccine, cells, listeria, immunol, monocytogenes, psa, antigen, immune, human, responses, recombinant, patients, listeriolysin, tumor, tumors, lmllopsa, cell, vaccines, immunotherapy, dendritic, clin, res, prostatespecific, privacy, cookies, content, paterson, regression, established, mouse, access, phase, dna, usa, immunother, publish, research, search, shahabi, attenuated, study, immunogenicity, antitumor,

Topics {✒️}

month download article/chapter hormone-refractory prostate cancer listeria monocytogenes-based vaccines recombinant live attenuated human prostate-specific antigen psa h2db-specific peptide homologues prime/boost regimen europium-labelled target cells listeria-based vaccines psa-based vaccines ifn-γ secreting cells immunotherapeutic target antigen pox psa vaccines recombinant bacterial vaccine prostate-specific antigen article cancer immunology live animal hosts recombinant human psa vaccinia viruses expressing full article pdf metastatic prostate cancer human papilloma virus-16 attenuated lm strain prostate specific antigens cancer-related death vaccine versus vaccine privacy choices/manage cookies psa-specific ctls effective vaccine vectors antigen density presented metastatic prostate tumors t-cell responses related subjects anti-tumor effects lm–llo–psa restricted ctl epitope anti-tumor immunity listeria monocytogenes enhances bioengineered listeria monocytogenes listeria monocytogenes pathogenicity cd4+cd25+ regulatory human psa gene circumventing immunoregulatory cells th1-type immunity strong immune responses humoral immune responses european economic area future diagnostic markers reveals subdominant epitopes immunodominant h-2d

Questions {❓}

Katz MH, McKiernan JM (2007) High-risk, clinically localized prostate cancer: is monotherapy adequate?
Yu P, Fu YX (2006) Tumor-infiltrating T lymphocytes: friends or foes?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Development of a Listeria monocytogenes based vaccine against prostate cancer
         description:Prostate specific antigen (PSA) is a likely immunotherapeutic target antigen for prostate cancer, the second leading cause of cancer-related death in American men. Previously, we demonstrated that attenuated strains of Listeria monocytogenes (Lm) can be used as effective vaccine vectors for delivery of tumor antigens causing regression of established tumors accompanied by strong immune responses toward these antigens in murine models of cancer. In the present study, we have developed and characterized a recombinant live attenuated L. monocytogenes/PSA (Lm–LLO–PSA) vaccine with potential use for the treatment of pCa. Human PSA gene was cloned into and expressed by an attenuated Lm strain. This recombinant bacterial vaccine, Lm–LLO–PSA was tested for stability, virulence, immunogenicity and anti-tumor effects in a murine model for pCa. Immunization with Lm–LLO–PSA was shown to lower the number of tumor infiltrating T regulatory cells and cause complete regression of over 80% of tumors formed by an implanted genetically modified mouse prostate adenocarcinoma cell line, which expressed human PSA. Lm–LLO–PSA was immunogenic in C57BL/6 mice and splenocytes from mice immunized with Lm–LLO–PSA showed significantly higher number of IFN-γ secreting cells over that of the naïve animals in response to a PSA H2Db-specific peptide, as measured by both, ELISpot and intracellular cytokine staining. In addition, using a CTL assay we show that the T cells specific for PSA were able to recognize and lyse PSA-peptide pulsed target cells in vitro. In a comparison study with two other PSA-based vaccines (a pDNA and a vaccinia vaccine), Lm–LLO–PSA was shown to be more efficacious in regressing established tumors when used in a homologues prime/boost regimen. Together, these results indicate that Lm–LLO–PSA is a potential candidate for pCa immunotherapy and should be further developed.
         datePublished:2008-02-14T00:00:00Z
         dateModified:2008-02-14T00:00:00Z
         pageStart:1301
         pageEnd:1313
         sameAs:https://doi.org/10.1007/s00262-008-0463-z
         keywords:
             Listeria monocytogenes
            PSA
            Cancer vaccine
            Immunotherapeutic
            Listeriolysin O
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig7_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig8_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig9_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig10_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:57
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Vafa Shahabi
               affiliation:
                     name:Advaxis, Inc
                     address:
                        name:Research and development, Advaxis, Inc, North Brunswick, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Mariela Reyes-Reyes
               affiliation:
                     name:Advaxis, Inc
                     address:
                        name:Research and development, Advaxis, Inc, North Brunswick, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anu Wallecha
               affiliation:
                     name:Advaxis, Inc
                     address:
                        name:Research and development, Advaxis, Inc, North Brunswick, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sandra Rivera
               affiliation:
                     name:Advaxis, Inc
                     address:
                        name:Research and development, Advaxis, Inc, North Brunswick, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yvonne Paterson
               affiliation:
                     name:University of Pennsylvania
                     address:
                        name:Department of Microbiology, University of Pennsylvania, Pennsylvania, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Paulo Maciag
               affiliation:
                     name:Advaxis, Inc
                     address:
                        name:Research and development, Advaxis, Inc, North Brunswick, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Development of a Listeria monocytogenes based vaccine against prostate cancer
      description:Prostate specific antigen (PSA) is a likely immunotherapeutic target antigen for prostate cancer, the second leading cause of cancer-related death in American men. Previously, we demonstrated that attenuated strains of Listeria monocytogenes (Lm) can be used as effective vaccine vectors for delivery of tumor antigens causing regression of established tumors accompanied by strong immune responses toward these antigens in murine models of cancer. In the present study, we have developed and characterized a recombinant live attenuated L. monocytogenes/PSA (Lm–LLO–PSA) vaccine with potential use for the treatment of pCa. Human PSA gene was cloned into and expressed by an attenuated Lm strain. This recombinant bacterial vaccine, Lm–LLO–PSA was tested for stability, virulence, immunogenicity and anti-tumor effects in a murine model for pCa. Immunization with Lm–LLO–PSA was shown to lower the number of tumor infiltrating T regulatory cells and cause complete regression of over 80% of tumors formed by an implanted genetically modified mouse prostate adenocarcinoma cell line, which expressed human PSA. Lm–LLO–PSA was immunogenic in C57BL/6 mice and splenocytes from mice immunized with Lm–LLO–PSA showed significantly higher number of IFN-γ secreting cells over that of the naïve animals in response to a PSA H2Db-specific peptide, as measured by both, ELISpot and intracellular cytokine staining. In addition, using a CTL assay we show that the T cells specific for PSA were able to recognize and lyse PSA-peptide pulsed target cells in vitro. In a comparison study with two other PSA-based vaccines (a pDNA and a vaccinia vaccine), Lm–LLO–PSA was shown to be more efficacious in regressing established tumors when used in a homologues prime/boost regimen. Together, these results indicate that Lm–LLO–PSA is a potential candidate for pCa immunotherapy and should be further developed.
      datePublished:2008-02-14T00:00:00Z
      dateModified:2008-02-14T00:00:00Z
      pageStart:1301
      pageEnd:1313
      sameAs:https://doi.org/10.1007/s00262-008-0463-z
      keywords:
          Listeria monocytogenes
         PSA
         Cancer vaccine
         Immunotherapeutic
         Listeriolysin O
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig7_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig8_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig9_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0463-z/MediaObjects/262_2008_463_Fig10_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:57
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Vafa Shahabi
            affiliation:
                  name:Advaxis, Inc
                  address:
                     name:Research and development, Advaxis, Inc, North Brunswick, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Mariela Reyes-Reyes
            affiliation:
                  name:Advaxis, Inc
                  address:
                     name:Research and development, Advaxis, Inc, North Brunswick, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anu Wallecha
            affiliation:
                  name:Advaxis, Inc
                  address:
                     name:Research and development, Advaxis, Inc, North Brunswick, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sandra Rivera
            affiliation:
                  name:Advaxis, Inc
                  address:
                     name:Research and development, Advaxis, Inc, North Brunswick, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yvonne Paterson
            affiliation:
                  name:University of Pennsylvania
                  address:
                     name:Department of Microbiology, University of Pennsylvania, Pennsylvania, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Paulo Maciag
            affiliation:
                  name:Advaxis, Inc
                  address:
                     name:Research and development, Advaxis, Inc, North Brunswick, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:57
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Advaxis, Inc
      address:
         name:Research and development, Advaxis, Inc, North Brunswick, USA
         type:PostalAddress
      name:Advaxis, Inc
      address:
         name:Research and development, Advaxis, Inc, North Brunswick, USA
         type:PostalAddress
      name:Advaxis, Inc
      address:
         name:Research and development, Advaxis, Inc, North Brunswick, USA
         type:PostalAddress
      name:Advaxis, Inc
      address:
         name:Research and development, Advaxis, Inc, North Brunswick, USA
         type:PostalAddress
      name:University of Pennsylvania
      address:
         name:Department of Microbiology, University of Pennsylvania, Pennsylvania, USA
         type:PostalAddress
      name:Advaxis, Inc
      address:
         name:Research and development, Advaxis, Inc, North Brunswick, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Vafa Shahabi
      affiliation:
            name:Advaxis, Inc
            address:
               name:Research and development, Advaxis, Inc, North Brunswick, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Mariela Reyes-Reyes
      affiliation:
            name:Advaxis, Inc
            address:
               name:Research and development, Advaxis, Inc, North Brunswick, USA
               type:PostalAddress
            type:Organization
      name:Anu Wallecha
      affiliation:
            name:Advaxis, Inc
            address:
               name:Research and development, Advaxis, Inc, North Brunswick, USA
               type:PostalAddress
            type:Organization
      name:Sandra Rivera
      affiliation:
            name:Advaxis, Inc
            address:
               name:Research and development, Advaxis, Inc, North Brunswick, USA
               type:PostalAddress
            type:Organization
      name:Yvonne Paterson
      affiliation:
            name:University of Pennsylvania
            address:
               name:Department of Microbiology, University of Pennsylvania, Pennsylvania, USA
               type:PostalAddress
            type:Organization
      name:Paulo Maciag
      affiliation:
            name:Advaxis, Inc
            address:
               name:Research and development, Advaxis, Inc, North Brunswick, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Research and development, Advaxis, Inc, North Brunswick, USA
      name:Research and development, Advaxis, Inc, North Brunswick, USA
      name:Research and development, Advaxis, Inc, North Brunswick, USA
      name:Research and development, Advaxis, Inc, North Brunswick, USA
      name:Department of Microbiology, University of Pennsylvania, Pennsylvania, USA
      name:Research and development, Advaxis, Inc, North Brunswick, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(152)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.4s.

LINK . SPRINGER . COM {}